Immune Reconstitution Inflammatory Syndrome
8
1
1
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
12.5%
1 terminated out of 8 trials
80.0%
-6.5% vs benchmark
25%
2 trials in Phase 3/4
50%
2 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (8)
PET Imaging and Lymph Node Assessment of IRIS in People With AIDS
Immune Reconstitution Syndrome in HIV-Infected Patients Taking Antiretroviral Therapy
Pediatric Urgent Start of Highly Active Antiretroviral Treatment (HAART)
Preventing TB-IRIS in High-risk Patients: a Randomized Placebo-controlled Trial of Prednisone
Prediction and Pathogenesis of the Immune Reconstitution Inflammatory Syndrome
Corticosteroids for Immune Reconstitution Inflammatory Syndrome (IRIS)
Paradoxical Tuberculosis Immune Reconstitution Inflammatory Syndrome (TB-IRIS) Treatment Trial
Maraviroc (CCR5) Antagonism to Decrease the Incidence of the Immune Reconstitution Inflammatory Syndrome in HIV-Infected Patients